UCSF Start-Up Shows Off Its Approach To K-Ras Inhibition
This article was originally published in Start Up
Executive Summary
In February, Janssen Biotech announced a collaboration with Araxes, a start-up out of the University of California, San Francisco. Now, with a publication in Nature, further details on the company have been revealed.
You may also be interested in...
Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach
SVP Elliott Levy said the company hasn't ruled out a tumor-agnostic approach for AMG 510, but Phase I data for the first-in-class drug show a bigger effect in lung cancer – a 50% response rate, so far – than in colorectal cancer patients with a KRAS G12C mutation.
Science Matters: Welcome To The Oncobiome
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
Science Matters: Targeting Heme Trafficking In A Variety Of Diseases
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.